CDCP1 antibodies and antibody drug conjugates
AssigneesBeth Israel Deaconess Medical Center, Inc., Pfizer Inc., Cornell University
InventorsLewis C. Cantley, Stephen P. Soltoff, Brooke M. Emerling, Georgios Poulogiannis, Cindy M. Hodakoski, Hui Liu, Irina Apostolou, Brian Gaither Bates, Kimberly Ann Marquette, Eric M. Bennett, Lidia Mosyak, Lioudmila G. Tchistiakova, Edward Christian Rosfjord, Isaac J. Rondon, Chao Bai Huang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.
Claims8
An isolated antibody, or antigen-binding fragment thereof, that specifically binds CDCP1, comprising:
- (i) a VH that comprises:
- (a) a CDRH1 comprising the amino acid sequence of SEQ ID NO:2,
- (b) a CDRH2 comprising the amino acid sequence of SEQ ID NO:3;
- and
- (c) a CDRH3 comprising the amino acid sequence of SEQ ID NO:27;
- and (ii) a VL that comprises:
- (a) a CDRL1 comprising the amino acid sequence of SEQ ID NO:12,
- (b) a CDRL2 comprising the amino acid sequence of SEQ ID NO:13;
- and
- (c) a CDRL3 comprising the amino acid sequence of SEQ ID NO:31.
An antibody drug conjugate comprising an antibody, or antigen-binding fragment thereof, that specifically binds CUB Domain-Containing Protein-1 (CDCP1), wherein the antibody is conjugated to a drug moiety, wherein the antibody, or antigen-binding fragment thereof, comprises:
- (i) a heavy chain variable region (VH) that comprises:
- (a) a VH complementarity determining region one (CDRH1) comprising the amino acid sequence of SEQ ID NO:
- 2,
- (b) a VH complementarity determining region two (CDRH2) comprising the amino acid sequence of SEQ ID NO:
- 3, and
- (c) a VH complementarity determining region three (CDRH3) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 27, SEQ ID NO:
- 4, SEQ ID NO:
- 40 and SEQ ID NO:
- 45,
- and (ii) a light chain variable region (VL) that comprises:
- (a) a VL complementarity determining region one (CDRL1) comprising the amino acid sequence of SEQ ID NO:
- 12,
- (b) a VL complementarity determining region two (CDRL2) comprising the amino acid sequence of SEQ ID NO:
- 13, and
- (c) a VL complementarity determining region three (CDRL3) comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 31 and SEQ ID NO:14.
Dependencies are inferred from the claim text.